Food, drugs, devices › SCA Pharmaceuticals
Drug recall: Heparin Sodium 5,000 units in 0.9% Sodium Chloride 1000 mL bag (5 units/mL), Rx Only, SCA Pharmaceuticals 755 Rainbow Rd
FDA enforcement event 85865 is a drug recall by SCA Pharmaceuticals of Windsor, CT, initiated 16 Jun 2020 and classified Class II, with 1 product record.
FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 64% of the 342 drug enforcement events initiated in 2020 carry the same class.
Status: Terminated, terminated 17 Mar 2021. Initiation: voluntary: firm initiated. SCA Pharmaceuticals has 19 enforcement events on this register, with a median of 1 product record per event.
Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.
Recalling firm
SCA Pharmaceuticals, Windsor, CT.
Reason for recall
"Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint."
Distribution
"Product was distributed to hospitals in PA and CA."
Product records
| Recall number | Product | Quantity | Class | Status | Report date |
|---|---|---|---|---|---|
| D-1311-2020 | Heparin Sodium 5,000 units in 0.9% Sodium Chloride 1000 mL bag (5 units/mL), Rx Only, SCA Pharmaceuticals 755 Rainbow Rd. Windsor, CT 06095, NDC 70004-0650-46 | 333 bags | Class II | Terminated | 24 Jun 2020 |
Context
Other enforcement events for SCA Pharmaceuticals
All 19 events for SCA Pharmaceuticals
Questions and answers
Why was this drug recalled?
FDA's record gives the reason for recall as: "Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint."
What does Class II mean?
FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Where was the product distributed?
FDA's distribution pattern field reads: "Product was distributed to hospitals in PA and CA."
Is the recall still ongoing?
FDA lists the status as Terminated; the termination date is 17 Mar 2021. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.
Where does this data come from?
openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.
Provenance
Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.